Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1501 for:    leukine
Previous Study | Return to List | Next Study

Biomarker Assessments of Leukine During Treatment of Parkinson's Disease

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03790670
Recruitment Status : Recruiting
First Posted : January 2, 2019
Last Update Posted : October 19, 2020
Sponsor:
Information provided by (Responsible Party):
Howard Gendelman, MD, University of Nebraska

Tracking Information
First Submitted Date  ICMJE December 18, 2018
First Posted Date  ICMJE January 2, 2019
Last Update Posted Date October 19, 2020
Actual Study Start Date  ICMJE January 30, 2019
Estimated Primary Completion Date September 30, 2022   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: October 15, 2020)
Incidence of Treatment-Associated Adverse Events [ Time Frame: monthly during the course of treatment, up to 24 months, followed by 1 month drug cessation ]
The safety of Leukine administration in PD will be examined by documenting abnormal results from CBC with differential, total T cell count, or comprehensive metabolic panel analyses; abnormal physical and or neurological exam findings; abnormal levels of antibodies to GM-CSF; clinically increasing Unified Parkinson's disease Rating Scale (UPDRS) part I, II, III, and IV scores as determined by the examining physician; and other adverse events. These safety assessments will be made every four weeks.
Original Primary Outcome Measures  ICMJE
 (submitted: December 27, 2018)
Incidence of Treatment-Associated Adverse Events [ Time Frame: monthly during the course of treatment, up to 6 months, followed by 1 month drug cessation ]
The safety of Leukine administration in PD will be examined by documenting abnormal results from CBC with differential, total T cell count, or comprehensive metabolic panel analyses; abnormal physical and or neurological exam findings; abnormal levels of antibodies to GM-CSF; clinically increasing Unified Parkinson's disease Rating Scale (UPDRS) part I, II, III, and IV scores as determined by the examining physician; and other adverse events. These safety assessments will be made every four weeks.
Change History
Current Secondary Outcome Measures  ICMJE
 (submitted: October 15, 2020)
  • Determination of Immune Cell Phenotype [ Time Frame: 24 months of treatment, followed by 1 month drug cessation ]
    Measurements will include change in CD45RO+ or FAS+ frequencies in CD4+ T cells; change in CD31+ frequencies in CD4+ T cells, Teff or Treg subsets; change in ItgB7+ frequencies in CD4+ T cells or the Teff subset; change in ItgB4B7+ frequencies in CD4+ T cells or the Treg subset; change in CD27+ frequencies in CD4+ T cells, Teff or Treg subsets, change in CCR7+ frequencies in CD4+ T cells, Teff or Treg subsets; change in FoxP3+ frequencies in CD4+ T cells, Teff or Treg subsets; change in CD34, CD117, or CD135 levels; change in DNA methylation status. The measurements will be combined to determine overall changes in immune cell frequency and T cell subset phenotype both on and off treatment.
  • Determination of Immune Cell Number [ Time Frame: 24 months of treatment, followed by 1 month drug cessation ]
    Measurements will include changes in levels of lymphocytes or CD4+ T cells, as well as T cell, B cell, and bone marrow progenitor subsets.
  • Determination of Immune Cell Function [ Time Frame: 24 months of treatment, followed by 1 month drug cessation ]
    Measurements will include changes in T cell function via proliferation and suppression assays and/or changes in B cell function via antibody production assessments.
Original Secondary Outcome Measures  ICMJE
 (submitted: December 27, 2018)
  • Determination of Immune Cell Phenotype [ Time Frame: 6 months of treatment, followed by 1 month drug cessation ]
    Measurements will include change in CD45RO+ or FAS+ frequencies in CD4+ T cells; change in CD31+ frequencies in CD4+ T cells, Teff or Treg subsets; change in ItgB7+ frequencies in CD4+ T cells or the Teff subset; change in ItgB4B7+ frequencies in CD4+ T cells or the Treg subset; change in CD27+ frequencies in CD4+ T cells, Teff or Treg subsets, change in CCR7+ frequencies in CD4+ T cells, Teff or Treg subsets; change in FoxP3+ frequencies in CD4+ T cells, Teff or Treg subsets; change in CD34, CD117, or CD135 levels; change in DNA methylation status. The measurements will be combined to determine overall changes in immune cell frequency and T cell subset phenotype both on and off treatment.
  • Determination of Immune Cell Number [ Time Frame: 6 months of treatment, followed by 1 month drug cessation ]
    Measurements will include changes in levels of lymphocytes or CD4+ T cells, as well as T cell, B cell, and bone marrow progenitor subsets.
  • Determination of Immune Cell Function [ Time Frame: 6 months of treatment, followed by 1 month drug cessation ]
    Measurements will include changes in T cell function via proliferation and suppression assays and/or changes in B cell function via antibody production assessments.
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE Biomarker Assessments of Leukine During Treatment of Parkinson's Disease
Official Title  ICMJE Safety, Tolerability and Biomarker Assessments of Leukine (Sargramostim) During Extended Timed Treatment for Parkinson's Disease: A Phase I Pilot Study
Brief Summary First, the investigators will determine the safety of a 24 month regimen of Leukine administered as a weight-based dose at 3 µg/kg/day for 5 days (week), followed by a 2-day holiday (weekend). This 24 month (n=10) pilot study will extend the prior 2 month observation tests towards the goal of assessing the safety of Leukine for treatment of Parkinson's disease (PD). Clinical signs and symptoms will be measured by personal well-being, physical, and neurological examinations (UPDRS Parts I, II, III, and IV assessments) and blood tests (CBC with differential, total T cell count, and a comprehensive metabolic sera panel). Second, we will assess regimen tolerability administered in a dose reduction, from 6 µg/kg/day without interruption, to 3 µg/kg/day with 2 day drug holidays. The investigators will examine over a time of 24 months, effects of treatment on defined adaptive immune deficits in PD as measured by analysis of peripheral blood mononuclear cells collected before, during, and after cessation of Leukine administration. Individual T cell parameters will be assessed and will include links between T cell function and subset analyses and clinical neurological signs and symptoms. In addition, the functional stability of the immune deficits will be assess in PD by examining T cell subsets in PD patients in this study against prior results. The investigators will also determine whether the immune deficits of PD are consistent during baseline data collection, and the potential Leukine-induced motor control and mobility improvements will be determined by UPDRS part I, II, III, and IV scores off treatment and on treatment.
Detailed Description

Primary Objectives: There are three study goals. First, the investigators will determine the safety of a 24 month regimen of Leukine administered as a weight-based dose at 3 µg/kg/day for 5 days (week), followed by a 2-day holiday (weekend). This 24 month (n=10) pilot study will extend the prior 2 month observation tests towards the goal of assessing the safety of Leukine for treatment of Parkinson's disease (PD). Clinical signs and symptoms will be measured by personal well-being, physical, and neurological examinations (UPDRS Parts I, II, III, and IV assessments) and blood tests (CBC with differential, total T cell count, and a comprehensive metabolic sera panel). Second, the investigators will assess regimen tolerability administered in a dose reduction, from 6 µg/kg/day without interruption, to 3 µg/kg/day with 2 day drug holidays. The lowered dose was chosen based on known tolerability and parallel-linked immune reconstitution seen in cancer-associated disease treatments. Due to fragility of the patient population and prior recorded adverse events the proposed dose reductions are justified.

Secondary Objectives:

Over a course of 24 months, the effects of treatment on defined adaptive immune deficits in PD as measured by analysis of peripheral blood mononuclear cells collected before, during, and after cessation of Leukine administration will be examined. Individual T cell parameters that include links between T cell function and subset analyses and clinical neurological signs and symptoms will be examined. These immune parameters will be serially examined as they may contribute to the immune deficits in PD. Thus, timed analyses of changes in T cell phenotypes and/or function will be completed. In addition, the investigators will assess the functional stability of the immune deficits in PD and will determine whether the immune deficits of PD are consistent during baseline data collection. The potential Leukine-induced motor control and mobility improvements will be determined by assessing UPDRS part I, II, III, and IV scores off treatment and on treatment. Specifically, over the course of this six-month treatment study, various biomarkers will be assessed including: T cell markers of immune activation, DNA methylation status, and B cell and bone marrow progenitor cell markers. We hope to uncover the time course of Treg induction, as well as link the pharmacokinetics of Leukine treatment (not previously recorded) to changes in specific biomarkers. Additionally, changes in the humoral response following extended Leukine treatment will be assessed by measuring the presence of antibodies against Leukine and alterations in B cell frequencies.

Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 1
Study Design  ICMJE Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE Parkinson Disease
Intervention  ICMJE Drug: sargramostim
Recombinant human GM-CSF produced by recombinant DNA technology using a yeast (S. cerevisiae) expression system
Other Name: Leukine
Study Arms  ICMJE Experimental: Leukine Treatment
24 month regimen of Leukine administered as a weight-based dose at 3 µg/kg/day for 5 days (week), followed by a 2-day holiday (weekend)
Intervention: Drug: sargramostim
Publications *

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Recruiting
Estimated Enrollment  ICMJE
 (submitted: October 15, 2020)
10
Original Estimated Enrollment  ICMJE
 (submitted: December 27, 2018)
5
Estimated Study Completion Date  ICMJE December 30, 2022
Estimated Primary Completion Date September 30, 2022   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • 1. Onset of bradykinesia and 1 or both of the following: rest tremor and/or rigidity

    2. Asymmetric onset of clinical signs

    3. Progressive motor symptoms

    4. Age at onset 35-85 years

    5. Duration of PD symptoms of at least 3 years

    6. Female subjects must be either:

    1. Not pregnant, not breastfeeding, and not planning on becoming pregnant during the study;
    2. Not of childbearing potential, defined as one who has been postmenopausal for at least 1 year and with follicle stimulating hormone (FSH) levels in the laboratory defined postmenopausal range, or has been surgically sterilized, or has had a hysterectomy at least 3 months prior to the start of this trial; or
    3. If of childbearing potential, must agree to use an effective method of avoiding pregnancy to the end of the trial and must have a negative serum beta-human chorionic gonadotropin (β-HCG) test. Effective methods of avoiding pregnancy are contraceptive methods used consistently and correctly (including implantable contraceptives, injectable contraceptives, oral contraceptives, transdermal contraceptives, intrauterine devices, diaphragm with spermicide, male or female condoms with spermicide, or cervical cap), abstinence, or a sterile sexual partner.

      7. Must be stage 4 or less according to the Hoehn and Yahr scale

      Exclusion Criteria:

  • 1. Atypical features indicative of a Parkinson-Plus disorder (Progressive Supranuclear Palsy (PSP), Multiple System Atrophy (MSA), Corticobasal Degeneration (CBD)) including cerebellar signs, supranuclear gaze palsy, apraxia and other cortical signs, or prominent autonomic failure

    2. Neuroleptic treatment at time of onset of parkinsonism

    3. Active treatment with a neuroleptic at time of study entry

    4. History of repeated strokes with stepwise progression of parkinsonism

    5. History of repeated head injury

    6. History of definite encephalitis

    7. More than one blood relative diagnosed with PD

    8. Prominent gait imbalance early in the course (< 5 years)

    9. Mini-mental state examination score <26

    10. Hematological malignancy or coagulopathy

    11. Abnormal blood analyses: hematocrit <30; WBC>11.5; clinically significant laboratory data (e.g. alanine aminotransferase [ALT] or aspartate aminotransferase [AST] 3x the upper limit of normal [ULN]), or any abnormal laboratory value that could interfere with the assessment of safety in the judgment of the investigator; significant abnormalities on the clinical examination, vital signs, and clinical chemistry or hematology results (excluding findings of Parkinson's disease), that may interfere with the study or present a safety risk for the subject as judged by the clinical investigator charged in the care of study participants

    12. Serious medical illness or co-morbidity that may interfere with participation in the study

    13. Brain surgery for parkinsonism (DBS, cell implantation, gene therapy)

    14. History of an autoimmune disorder or systemic inflammatory disorder deemed significant by physician

    15. Immunostimulatory or immunosuppressive treatment (including amphet-amines or systemic corticosteroids) within 90 days

    16. Exclusively unilateral parkinsonism for longer than 3 years

    17. Known hypersensitivity to GM-CSF, yeast-derived products

    18. Current lithium treatment

    19. Individuals with current diagnoses of alcohol or substance abuse/dependence

    20. Anyone who is not appropriate for participation in this research protocol as deemed by the principal or co-investigator

    21. Anyone who has previously been treated with GM-CSF as an immunomodulatory therapy

    22. Anyone with poor venous access

Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 35 Years to 85 Years   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE
Contact: Katherine Olson, PhD 4025592547 katherine.olson@unmc.edu
Contact: Melinda Wojtkiewicz, B.S 402-559-0856 melinda.wojtkiewicz@unmc.edu
Listed Location Countries  ICMJE United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT03790670
Other Study ID Numbers  ICMJE 839-18-FB
Has Data Monitoring Committee Yes
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No
IPD Sharing Statement  ICMJE
Plan to Share IPD: No
Responsible Party Howard Gendelman, MD, University of Nebraska
Study Sponsor  ICMJE University of Nebraska
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Principal Investigator: Howard Gendelman, MD UNMC
PRS Account University of Nebraska
Verification Date October 2020

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP